If they don't know enough about the cancer immunotherapy space to get basic facts straight, why should investors trust them to know what they are buying?
Just a matter of time before they go from "undevalued" to "devalued"
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.